Skip to main content

Table 5 Comparison of clinical response between ANA titer increased and no-change patients

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

  ANA after IFX  
EULAR Increased No change P value a
response (n = 13) (n = 76)  
Good 8% 54% 0.001
(Remission) (0) (42%) 0.001
Moderate 15% 20% 0.001
No 77% 26% 0.001
  1. ANAs, antinuclear antibodies; IFX, infliximab.
  2. aAnalyzed with χ2 test.